| 产品描述: | CY-09是一种特异的NLRP3 inflammasome的抑制剂,直接靶向NLRP3。它对5种主要的cytochrome P450酶的IC50值分别为18.9, 8.18, >50, >50 和 26.0 µM |
| 靶点: |
NLRP3 inflammasome;NOD-likeReceptor(NLR); NOD |
| 体外研究: |
CY-09 specifically blocks NLRP3 activation in macrophages. CY-09 inhibits NLRP3 oligomerization and inflammasome assembly. CY-09 directly binds to NLRP3 and inhibits its ATPase activity. The metabolic stability of CY-09 was first evaluated using human and mouse liver microsomes, exhibiting favorable stability with the half-life >145 min for both human and mouse microsomes. The metabolic stability of CY-09 was first evaluated using human and mouse liver microsomes, exhibiting favorable stability with the half-life >145 min for both human and mouse microsomes, which exhibited low risk of drug-drug interactions |
| 体内研究: |
CY-09 inhibits NLRP3 activation in vivo and prevents neonatal lethality in a mouse model of CAPS. In pharmacokinetic studies evaluted in C57BL/6J mice administered a single i.v. or oral dose, CY-09 exhibits favorable pharmacokinetics, with a half-life of 2.4 h, an area under the curve of 8,232 (h·ng)/ml, and bioavailability of 72%. CY-09 reverses metabolic disorders in diabetic mice by inhibition of NLRP3-dependent inflammation. CY-09 treatment has remarkable beneficial effects for metainflammation, hyperglycemia, and insulin resistance in diabetic mice |
| 细胞实验: |
Cell lines: BMDMs and PBMCs Concentrations: 1, 5, and 10 μM Incubation Time: 30 min Method: 5 × 105/ml BMDMs and 6 × 106/ml PBMCs were plated in 12-well plates. The following morning, the medium was replaced, and cells were stimulated with 50 ng/ml LPS or 400 ng/ml Pam3CSK4 (for noncanonical inflammasome activation) for 3 h. After that, CY-09 or other inhibitors were added into the culture for another 30 min, and then the cells were stimulated for 4 h with MSU (150 µg/ml), Salmonella typhimurium (multiplicity of infection) or for 30 min with ATP (2.5 mM) or nigericin (10 µM). Cells were transfected with poly(dA:dT) (0.5 µg/ml) for 4 h or LPS (500 ng/ml) overnight. Cell extracts and precipitated supernatants were analyzed by immunoblot. |
| 动物实验: |
Animal Models: C57BL/6J mice Dosages: 5 and 10 mg/kg Administration: i.v. and oral administration |
| 参考文献: |
1. Jiang H, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017, 214(11):3219-3238. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.362 ml |
11.808 ml |
23.617 ml |
| 5 mM |
0.472 ml |
2.362 ml |
4.723 ml |
| 10 mM |
0.236 ml |
1.181 ml |
2.362 ml |
| 50 mM |
0.047 ml |
0.236 ml |
0.472 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |